Hims and Ro are the two largest direct-to-consumer telehealth brands in the category. They score similarly (82 vs 80). The biggest difference: Ro's dose-step pricing gives it a lower starting price but maintenance pricing can match or exceed Hims's tiered structure.
Side-by-side
| Dimension | Hims & Hers | Ro Body |
|---|---|---|
| Editorial score | 82/100 | 80/100 |
| Semaglutide | $199/mo | $149+ dose-step |
| Tirzepatide | $269/mo | $229+ dose-step |
Who should pick Hims & Hers
Patients who already have Hims/Hers subscriptions and value single-platform simplicity; patients who prefer Hims's brand UX.
Who should pick Ro Body
Patients with insurance coverage who want optional branded GLP-1 routing; patients comfortable with dose-step pricing.
Frequently asked
Which is cheaper at maintenance?
Close. Hims tiered structure: ~$199/mo. Ro dose-step: $149 starting → $199+ at maintenance. Both run significantly higher than category-leader NexLife at $145/mo flat.
Which has better insurance routing?
Ro has a more developed insurance-routed branded GLP-1 path through Ro+Wegovy/Zepbound integrations.
Which to pick?
If you have insurance for branded, look at Ro. If brand UX matters most, look at Hims. If cost matters most, see NexLife at 94/100.